vs
EXACT SCIENCES CORP（EXAS）与TRINET GROUP, INC.（TNET）财务数据对比。点击上方公司名可切换其他公司
TRINET GROUP, INC.的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），EXACT SCIENCES CORP同比增速更快（23.1% vs -2.2%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $43.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
TriNet Group, Inc.是一家面向中小企业的专业雇主组织，总部位于加州都柏林，服务员工规模在3至2500人之间的各类机构。可提供薪资管理、健康福利管理服务，还能为客户提供劳动法规合规、风险降低相关咨询，可作为外包人力资源部门为企业分担人事相关事务。
EXAS vs TNET — 直观对比
营收规模更大
TNET
是对方的1.4倍
$878.4M
营收增速更快
EXAS
高出25.3%
-2.2%
自由现金流更多
EXAS
多$77.4M
$43.0M
两年增速更快
EXAS
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | — |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 0.1% |
| 净利率 | -9.8% | — |
| 营收同比 | 23.1% | -2.2% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASTNET
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.2B | ||
| Q2 25 | $811.1M | $1.2B | ||
| Q1 25 | $706.8M | $1.3B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.2B | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.3B |
净利润EXASTNET
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $34.0M | ||
| Q2 25 | $-1.2M | $37.0M | ||
| Q1 25 | $-101.2M | $85.0M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $45.0M | ||
| Q2 24 | $-15.8M | $60.0M | ||
| Q1 24 | $-110.2M | $91.0M |
毛利率EXASTNET
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASTNET
| Q4 25 | -9.4% | 0.1% | ||
| Q3 25 | -3.0% | 4.1% | ||
| Q2 25 | -0.3% | 4.1% | ||
| Q1 25 | -13.6% | 8.9% | ||
| Q4 24 | -122.8% | -2.9% | ||
| Q3 24 | -5.6% | 4.7% | ||
| Q2 24 | -3.8% | 6.5% | ||
| Q1 24 | -16.7% | 9.7% |
净利率EXASTNET
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 2.8% | ||
| Q2 25 | -0.1% | 3.0% | ||
| Q1 25 | -14.3% | 6.6% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 3.6% | ||
| Q2 24 | -2.3% | 4.9% | ||
| Q1 24 | -17.3% | 7.2% |
每股收益（稀释后）EXASTNET
| Q4 25 | $-0.45 | $0.02 | ||
| Q3 25 | $-0.10 | $0.70 | ||
| Q2 25 | $-0.01 | $0.77 | ||
| Q1 25 | $-0.54 | $1.71 | ||
| Q4 24 | $-4.69 | $-0.44 | ||
| Q3 24 | $-0.21 | $0.89 | ||
| Q2 24 | $-0.09 | $1.20 | ||
| Q1 24 | $-0.60 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $287.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $54.0M |
| 总资产 | $5.9B | $3.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASTNET
| Q4 25 | $964.7M | $287.0M | ||
| Q3 25 | $1.0B | $321.0M | ||
| Q2 25 | $858.4M | $407.0M | ||
| Q1 25 | $786.2M | $349.0M | ||
| Q4 24 | $1.0B | $360.0M | ||
| Q3 24 | $1.0B | $301.0M | ||
| Q2 24 | $946.8M | $249.0M | ||
| Q1 24 | $652.1M | $383.0M |
股东权益EXASTNET
| Q4 25 | $2.4B | $54.0M | ||
| Q3 25 | $2.5B | $110.0M | ||
| Q2 25 | $2.5B | $107.0M | ||
| Q1 25 | $2.4B | $63.0M | ||
| Q4 24 | $2.4B | $69.0M | ||
| Q3 24 | $3.2B | $129.0M | ||
| Q2 24 | $3.2B | $100.0M | ||
| Q1 24 | $3.1B | $143.0M |
总资产EXASTNET
| Q4 25 | $5.9B | $3.8B | ||
| Q3 25 | $5.9B | $3.4B | ||
| Q2 25 | $5.8B | $3.7B | ||
| Q1 25 | $5.7B | $3.8B | ||
| Q4 24 | $5.9B | $4.1B | ||
| Q3 24 | $6.7B | $3.7B | ||
| Q2 24 | $6.7B | $3.7B | ||
| Q1 24 | $6.4B | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $61.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $43.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 3.4% |
| 资本支出强度资本支出/营收 | 3.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $234.0M |
8季度趋势，按日历期对齐
经营现金流EXASTNET
| Q4 25 | $151.7M | $61.0M | ||
| Q3 25 | $219.9M | $72.0M | ||
| Q2 25 | $89.0M | $75.0M | ||
| Q1 25 | $30.8M | $95.0M | ||
| Q4 24 | $47.1M | $65.0M | ||
| Q3 24 | $138.7M | $84.0M | ||
| Q2 24 | $107.1M | $39.0M | ||
| Q1 24 | $-82.3M | $91.0M |
自由现金流EXASTNET
| Q4 25 | $120.4M | $43.0M | ||
| Q3 25 | $190.0M | $55.0M | ||
| Q2 25 | $46.7M | $57.0M | ||
| Q1 25 | $-365.0K | $79.0M | ||
| Q4 24 | $10.7M | $47.0M | ||
| Q3 24 | $112.6M | $59.0M | ||
| Q2 24 | $71.2M | $22.0M | ||
| Q1 24 | $-120.0M | $73.0M |
自由现金流率EXASTNET
| Q4 25 | 13.7% | 3.4% | ||
| Q3 25 | 22.3% | 4.5% | ||
| Q2 25 | 5.8% | 4.6% | ||
| Q1 25 | -0.1% | 6.1% | ||
| Q4 24 | 1.5% | 3.7% | ||
| Q3 24 | 15.9% | 4.8% | ||
| Q2 24 | 10.2% | 1.8% | ||
| Q1 24 | -18.8% | 5.8% |
资本支出强度EXASTNET
| Q4 25 | 3.6% | 1.4% | ||
| Q3 25 | 3.5% | 1.4% | ||
| Q2 25 | 5.2% | 1.5% | ||
| Q1 25 | 4.4% | 1.2% | ||
| Q4 24 | 5.1% | 1.4% | ||
| Q3 24 | 3.7% | 2.0% | ||
| Q2 24 | 5.1% | 1.4% | ||
| Q1 24 | 5.9% | 1.4% |
现金转化率EXASTNET
| Q4 25 | — | — | ||
| Q3 25 | — | 2.12× | ||
| Q2 25 | — | 2.03× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
TNET
| Insurance Services | $1.1B | 85% |
| Professional Services | $169.0M | 14% |
